DESCRIPTION OF TECHNOLOGY. (Please attach any draft manuscript, if available) In describing the Technology you should try to answer the question “what problem does the technology solve?”
DESCRIPTION OF TECHNOLOGY. In pursuit of an effective vaccine to end the global HIV-1/AIDS pandemic, researchers at the Vaccine Research Center (‘‘VRC’’) continue to study the structure of HIV-1. Recently, these researchers have determined the three- dimensional structure of the HIV-1 Envelope trimeric ectodomain (‘‘Env’’), comprised of three gp120 and three gp41 subunits, in its prefusion, mature, closed conformation. The researchers hypothesize that immunization with the prefusion, closed HIV-1 Env protein will elicit a neutralizing immune response. The VRC researchers engineered a portion of the HIV-1 Env trimer to stabilize it in this closed conformation for use as an immunogen. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. trimeric pre-fusion HIV-1 Env. Nature. 2014 Oct 23; 514(7523):455–61. [PMID: 25296255]. Intellectual Property: HHS Reference Number E–178–2014 includes U.S. Provisional Patent Application No. 62/ 046,059 filed September 4, 2014; U.S. Provisional Patent Application No. 62/ 136,480 filed March 21, 2015; PCT Application No. PCT/US2015/048729 filed September 4, 2015; U.S. Patent Application No. 15/508,885 filed March 3, 2017; and EPO Patent Application No. 15766697.5 filed March 29, 2017. Licensing Contact: Xx. Xxxxx Xxxxxxxxxx, 240–627–3674; xxxxx.xxxxxxxxxx@xxx.xxx. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize HIV-1 immunogens for treating or preventing HIV-1 infection. For collaboration opportunities, please contact Xx. Xxxxx Xxxxxxxxxx, 240–627– 3674; xxxxx.xxxxxxxxxx@xxx.xxx. Dated: June 14, 2018. Xxxxxxx X. Xxxxxxx, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2018–13416 Filed 6–21–18; 8:45 am] BILLING CODE 4140–01–P Place: National Institutes of Health, 0000 Xxxxxxx Xxxx, Xxxxxxxx, XX 00000 (Virtual Meeting).
DESCRIPTION OF TECHNOLOGY. Available for licensing and commercial development are patent rights that cover the uses of a p53 specific microRNA (xxXXX). It has been reported that the tumor suppressive mRNA miR–34a (a downstream target of p53) is downregulated in HPV-infected primary keratinocytes. miR–34a arrests the cell cycle at G2 phase and promotes apoptosis. Therapeutic restoration of normal expression levels of miR–34a and/or simultaneous stabilization of p53 (inhibited by HPV E6) induces miR–34a accumulation in G0/G1 phase and can arrest tumor growth. Neoplasia and cancer cell progression has also been associated with p18Ink4c overexpression which can be regulated with the introduction of a therapeutic amount of miR–34a. Tumor reduction/ suppression by down regulating p18Ink4c is also a therapeutic benefit provided by this invention. Applications: Cervical cancer; Human papillomavirus; Therapeutics.
DESCRIPTION OF TECHNOLOGY. (1) Cold plasma equipment with dual electric field gas supply The patent solves the problem: the cold plasma biological interaction treatment adopts dual electric field treatment to improve production efficiency, and more importantly, improve the position of the gas supply inlet and improve the processing quality.
DESCRIPTION OF TECHNOLOGY. SUMMARY OF TECHNOLOGY
DESCRIPTION OF TECHNOLOGY. All of the intellectual property and other rights related to the technology referred to as the Filex.xxx, Xxlexxxxx.xxx, XX3.xxx, XxbSxxxx.xxx, Xxemxx.xxx xxx SharxXxxxx.xxx xxx sites (the "Web Sites"), including but not limited to, all patent, copyright, trade secret and trademark rights, and all right to apply for any registrations thereof, all know-how, system design documents, detailed design documents, user specification documents, data processing algorithms, database schemas, stored procedures, active server page scripts in source code and in object code formats and html files (to the extent that any of the foregoing relate, directly or indirectly, to or are useful in connection with, the Web Sites).
DESCRIPTION OF TECHNOLOGY. All right, title and interest of Assignor and of all persons claiming by, through and under Assignor in, to and under all intellectual property or other rights of any kind or description relating to the “CHRM” software development project currently being pursued by BroadVision, Inc. and its affiliates, however such rights may have been developed or acquired and whether or not such rights have been reduced to writing. The types of rights assigned hereby include, without limitation: (a) trade secrets, inventions, ideas, processes, computer source and object code, data, formulae, programs, other works of authorship, know-how, improvements, discoveries, developments, designs, and techniques; (b) information regarding products, services, plans for research and development, marketing and business plans, budgets, financial statements, contracts, prices, suppliers, and customers; (c) information regarding the skills and compensation of employees, contractors, and any other service providers; and (d) the existence of any business discussions, negotiations, or agreements with any third party.
DESCRIPTION OF TECHNOLOGY
